Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corporate VC Backing Influences Private M&A Step-Ups

This article was originally published in Start Up

Executive Summary

New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.
Advertisement

Related Content

Corporate Venture "Parents" Rarely Buy Or Partner With Biotech Investments
Corporate Investors Boost M&A Step-Ups, But Not IPOs
Financings Of The Fortnight Ponders The Meaning Of The Best Year For Biotech IPOs Since 2007
Corporate VCs Step Up Carefully to Fill VC Void
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Corporate Venture Takes Center Stage
Corporate Venture Takes Center Stage

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel